About Triangle Pharmaceuticals
Triangle Pharmaceuticals is a Healthcare company based in Staten Island (United States) founded in 1994, and was acquired by Alcami in January 2020. Nucleoside analogs for HIV Hepatitis-B. Triangle Pharmaceuticals has raised $135.2 million across 4 funding rounds from investors including Gilead, Abbott and Alcami. The company was acqui-hired. Triangle Pharmaceuticals offers products and services including Drug Product Manufacturing, Laboratory Services, and Pharmaceutical Storage. Its focus areas include Life Sciences, Infectious Diseases, Drugs and Viral. Its legal entity is Alcami Corporation. Its competitors include Moderna, Adaptive Biotechnologies and Generate Biomedicines; 3 of its 3 listed competitors have raised funding.
Company details
Triangle Pharmaceuticals was a specialty pharmaceutical company was developing antiviral drug candidates with a particular focus on therapies for the HIV and the hepatitis B virus. Its lead product Coviracil, a nucleoside reverse transcriptase inhibitor was in Phase 3 trials for the treatment of HIV. It was also developing Amdoxovir, a guanosine nucleoside analog for HIV and Clevudine, a pyrimidine nucleoside analog for chronic Hepatitis B. In December 2002, Gilead acquired Triangle Pharmaceuticals for 464M.
- Headquarters Staten Island, United States
- Stage Acquired
- SectorsHealthcare
- Website tripharm.com
- Social LinkedIn
- Acquired by Alcami (Jan 2020)
- Legal Name Alcami Corporation
Products & Services of Triangle Pharmaceuticals
Triangle Pharmaceuticals offers a comprehensive portfolio of products and services, including Drug Product Manufacturing, Laboratory Services, and Pharmaceutical Storage.
Offers sterile and oral solid dose production for pharmaceuticals.
Provides testing and method development for pharma and biologics.
Delivers secure cGMP storage with calibration and validation.
Funding Insights of Triangle Pharmaceuticals
Triangle Pharmaceuticals has successfully raised a total of $135.2M across 4 strategic funding rounds. The most recent funding activity was a Private Equity Round of $58.2 million completed in March 2001. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $135.2M
- Total Rounds 4
- Last Round Private Equity Round — $58.2M
- Investors Count 2
All 4 funding rounds of Triangle Pharmaceuticals with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
4 investors in total: 4 institutional.
Investors in Triangle Pharmaceuticals
Triangle Pharmaceuticals has secured backing from 4 investors, including institutional and venture fund investors. Prominent investors backing the company include Gilead, Abbott and Alcami.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Venture capital firm focused on tech sectors | venrock.com | Palo Alto, United States | ||
Developer of medical devices, generic pharmaceuticals, and nutrition products | 1888 | abbott.com | Libertyville, United States | |
Developer of medicines to treat HIV/AIDS, liver diseases, cancer & others | 1987 | gilead.com | Foster City, United States | |
End-to-end small molecule development and manufacturing are provided for pharmaceuticals. | 2016 | alcaminow.com | Wilmington, United States |
Investor details for Triangle Pharmaceuticals
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Timeline of Triangle Pharmaceuticals
5 dated milestones of Triangle Pharmaceuticals across 26 years, from founding to its latest funding, stage changes and deals.
Competitors of Triangle Pharmaceuticals
Triangle Pharmaceuticals has 3 listed competitors in our database, 3 of them funded. They include Moderna, Adaptive Biotechnologies and Generate Biomedicines.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| modernatx.com | 2010 | Cambridge, United States | $2.78B | 1,312 | mRNA-based therapeutics for diseases including cancer and infections are developed. | |
| adaptivebiotech.com | 2009 | Seattle, United States | $419.15M | 609 | Clinical diagnostics and drug discovery for immune diseases are provided. | |
| generatebiomedicines.com | 2018 | Somerville, United States | $643M | 286 | Developer of novel protein-based therapeutics using machine learning and biological engineering |
Detailed competitors of Triangle Pharmaceuticals
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Top companies in Infectious Diseases
3 companies that operate in the same segment as Triangle Pharmaceuticals (Infectious Diseases) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Developer of molecular diagnostic testing solutions | 1996 | Sunnyvale, California, United States | USD 19.1 M | USD 54.88 M | 208 | |
Therapeutics for drug-resistant bacterial infections are developed. | 2013 | Cambridge, Massachusetts, United States | USD 114.7 M | USD 59.62 M | 32 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Triangle Pharmaceuticals
Complete news archive for Triangle Pharmaceuticals
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Triangle Pharmaceuticals
Triangle Pharmaceuticals was founded in 1994 and raised its 1st funding round 1 year after it was founded.
Triangle Pharmaceuticals is headquartered in Staten Island, United States. It is registered at Staten Island, New York, United States.
Triangle Pharmaceuticals is a funded company, having raised a total of $135.2M across 4 funding rounds to date.
Triangle Pharmaceuticals was a specialty pharmaceutical company was developing antiviral drug candidates with a particular focus on therapies for the HIV and the hepatitis B virus. Its lead product Coviracil, a nucleoside reverse transcriptase inhibitor was in Phase 3 trials for the treatment of HIV. It was also developing Amdoxovir, a guanosine nucleoside analog for HIV and Clevudine, a pyrimidine nucleoside analog for chronic Hepatitis B. In December 2002, Gilead acquired Triangle Pharmaceuticals for 464M.
Triangle Pharmaceuticals's top competitors include Moderna, Adaptive Biotechnologies and Generate Biomedicines.
Triangle Pharmaceuticals offers Drug Product Manufacturing, Laboratory Services, and Pharmaceutical Storage.
Triangle Pharmaceuticals operates through Alcami Corporation.
Yes. Triangle Pharmaceuticals was acquired by Alcami in January 2020.